GlassScriptPhysician profile
Stephanie Zwonitzer
NPI 1013457050
$16,310.05
in general payments reported to CMS, 2019-2025
54 companies · $5,071 in 2025
The $5,071 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,233 · 2022: $2,738 · 2023: $3,316 · 2024: $2,951 · 2025: $5,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,377 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Travel and Lodging: $474 · Education: $353 · Consulting Fee: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,377.09 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Travel and Lodging | $474.21 |
| Education | $352.60 |
| Consulting Fee | $135.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,019.76 | 2022-2025 | Ams 700, Ams 800 Artificial Urinary Sphincter, Wavewriter Alpha Prime 16 |
| Janssen Biotech, INC. | $1,197.49 | 2021-2025 | Erleada, Akeega, Balversa |
| Sumitomo Pharma America, INC. | $1,060.65 | 2023-2025 | Gemtesa, Orgovyx |
| Teleflex LLC | $897.93 | 2021-2025 | Urolift, Barrigel |
| Astellas Pharma US INC | $888.52 | 2021-2025 | Myrbetriq, Xtandi, Veozah |
| Endo Pharmaceuticals INC. | $815.98 | 2021-2024 | Xiaflex, Edex, Aveed |
| Urovant Sciences INC | $717.48 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $696.22 | 2021-2025 | |
| Abbvie INC. | $571.67 | 2021-2025 | |
| Antares Pharma, INC. | $492.80 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Coloplast Corp | $410.90 | 2023-2025 | Speedicath |
| Endo USA, INC. | $392.58 | 2024-2025 | Xiaflex, Aveed, Edex |
| Axonics, INC. | $390.26 | 2024 | Axonics |
| Pfizer INC. | $347.00 | 2021-2025 | |
| Tolmar, INC. | $342.52 | 2023-2025 | Eligard, Jatenzo |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Zwonitzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.